Frequency and Risk Factors for Post Mastectomy Pain Syndrome [PMPS] in Female Breast Cancer patients

2021 ◽  
Vol 15 (10) ◽  
pp. 2530-2533
Author(s):  
Said Zaman Khan ◽  
Sabih Nofil ◽  
Anum Arif ◽  
Maria Mir Jan ◽  
Bismah Riaz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Neuropathic Pain ◽  
Pain Syndrome ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Inclusion Criteria ◽  
Female Breast ◽  
Postoperative Risk

Post mastectomy pain syndrome is one of the most common complications after axillary surgery for breast cancer. PMPS is considered a neuropathic pain and is thought to be caused by a variety of pre-operative, intraoperative and postoperative risk factors. In this study all post operative patients for breast cancer were interviewed at follow-up visits for symptoms of pain according to DN4 neuropathic pain score questionnaire and VAS scale for pain intensity. A total of 97 patients were included according to inclusion criteria. Among them 24(24.74%) patients were having PMPS and 73(77.06%) were having no PMPS. Among risk factors, ALND was found to be the most important risk factor for development of PMPS. In most patients the pain was mild in intensity according to VAS scale. And site of the pain was mostly found to be ipsilateral chest wall and axilla and majority of patients pin responded to simple NSAIDS and Arm exercises. Keywords: Breast cancer, mastectomy, pain

scholarly journals Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients

Biology ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 566
Author(s):  
Sherihan AbdelHamid ◽  
Hala El-Mesallamy ◽  
Hany Abdel Aziz ◽  
Abdel-Rahman Zekri
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Female Breast ◽  
Mutation Carriers ◽  
Clinical Records

Evidence on the prognostic relevance of BRCA1/2 mutations on breast cancer survival is still debatable. To address this ambiguity, we sought to elucidate the impact of BRCA1/2 mutation carriership on long-term clinical outcomes for the first time in Egyptian female breast cancer patients. This study comprised 103 Egyptian female breast cancer patients previously tested for BRCA1/2 mutations. Clinicopathological characteristics and long-term follow-up data were retrieved from clinical records until death or loss to follow-up. Overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and metastasis-free survival (MFS) were compared in BRCA1/2 mutation carriers and non-carriers. Pathogenic variants (Class 5 according to ACMG/AMP guidelines) were observed in 29 cases. The profile of the detected variants was previously reported. After median follow-up time of 6.9 years (range, 4.2–24.4 years), BRCA1/2 carriers exhibited significantly worse RFS compared to non-carriers (p = 0.01; HR = 3.00 (95%CI 1.35–6.68)). However, we couldn’t demonstrate statistically significant difference between carriers of pathogenic mutations and non-carriers regarding MFS (p = 0.24; HR = 1.38 (95%CI 0.8–2.4)), DFS (p = 0.11; HR = 1.23 (95%CI 0.74–2.06)), or OS (p = 0.36; HR = 1.23 (95%CI 0.58–2.61)). Though no significant impact was observed in OS, yet BRCA1/2 mutation carriers were at high risk of recurrence, highlighting the importance of adopting BRCA screening strategies and prophylactic measures.

scholarly journals BRCA1/2 Mutations and Long-Term Clinical Outcomes in Egyptian Breast Cancer Patients

2021 ◽  
Vol 107 (1_suppl) ◽  
pp. 4-4
Author(s):  
SG AbdelHamid ◽  
HO El-Mesallamy ◽  
HM AbdelAziz ◽  
ARN Zekri
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Free Survival ◽  
Female Breast ◽  
Brca Carriers

Introduction: Clinical findings regarding the impact of BRCA1/2 mutational status on the prognosis of breast cancer patients are still controversial. We aimed to investigate the prognostic relevance of BRCA1/ 2 mutations on recurrence and long-term survival, for the first time, in Egyptian female breast cancer patients. Patients and Methods: The study cohort comprised 103 Egyptian female breast cancer patients previously tested for BRCA1/2 mutations using HRM analysis and direct sequencing. Clinicopathological and long-term clinical follow-up data including date and site of disease progression, were retrieved from medical records until death or loss to follow-up. Outcome measures including overall survival (OS), disease-free survival (DFS), recurrence-free survival, and metastasis-free survival (MFS) were compared in all BRCA1/ 2 mutation carriers versus non-carriers at 2, 5, 10, and 15 years after diagnosis. Results: The profile of the detected variants was previously reported. The American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines were used to re-classify the variants. The median follow-up time was 6.9 years (range, 4.2-24.4 years). BRCA carriers had significantly worse DFS than non-carriers, at 2 years 86.7% vs 88.2%; at 5 years 38.1% vs 57.8%; and at 10 years 21.6% vs 34.1% ( P=0.024). Negative estrogen receptor (ER) status (HR=2.44, 95%CI=1.33-4.47) and large tumor size (HR=2.19, HR=1.21-3.98) were also significant factors for worse DFS. Recurrence-free survival was significantly worse in BRCA carriers compared to non-carriers, at 5 years: 95.2% vs 98.2%; at 10 years: 54.4% vs 79.8%; and at 15 years 34.6% vs 61.7% ( P=0.005). BRCA carriers showed poorer OS and MFS, though not statistically significant [OS in BRCA carriers and non-carriers at 5 years: 81.6% vs 89.3%; at 10 years: 59.2% vs 60.6%; and at 15 years: 36.3 vs 59.2% ( P=0.42); and MFS at 2 years 86.7% vs 88.1%; at 5 years 44.5% vs 61.1% ; and at 10 years: 25.3% vs 38.2% ( P=0.41)]. Conclusion: To our knowledge, this is the first study in the Middle East to investigate long-term survival outcome of BRCA1/2 related breast cancer. We, herein, underline the necessity of implementing BRCA screening strategies and intensive surveillance in the mainstream oncology practice in Egypt.

Treatment disparities in female breast cancer patients according to race, ethnicity and socioeconomic status

2013 ◽  
Author(s):  
Christopher S. Bartlett ◽  
Tulay Koru-Sengul ◽  
Feng Miao ◽  
Stacey L. Tannenbaum ◽  
David J. Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Socioeconomic Status ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Female Breast ◽  
Treatment Disparities ◽  
Race Ethnicity

Sleeping Quality, Negative Emotions & Awakening Cortisol Level in Chinese Female Breast Cancer Patients Undergoing Radiotherapy Treatment

2013 ◽  
Author(s):  
Rainbow T. H. Ho ◽  
Irene K. M. Cheung ◽  
Cecilia L. W. Chan ◽  
Paul S. F. Yip ◽  
Phyllis H. Y. Lo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cortisol Level ◽  
Negative Emotions ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Female Breast ◽  
Radiotherapy Treatment

scholarly journals Study of Gene Expression of Programmed Cell Death Ligand 1 (PD-L1) in Breast Cancer Patients

2021 ◽  
Vol 107 (1_suppl) ◽  
pp. 2-2
Author(s):  
H Gadelrab ◽  
M Mokhtar ◽  
H Morsy ◽  
M Elnaggar
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cancer Patients ◽  
Therapeutic Response ◽  
Female Breast Cancer ◽  
Clinicopathological Parameters ◽  
Breast Cancer Patients ◽  
Expression Levels ◽  
Female Breast

Introduction: Breast cancer is the most frequently occurring cancer among females and the second most common cancer overall. Programmed Cell Death Ligand 1 (PD-L1) plays an important role in blocking ‘cancer-immunity cycle’ and is considered as a major inhibitory pathway. The aim of the present study was to clarify the alterations of expression of PD-L1 in peripheral blood mononuclear cytes (PBMCs) of female breast cancer patients and analyze its association with clinico-pathological criteria as well as therapeutic response. Materials and Methods: The study was conducted on 45 female breast cancer patients and 45 female controls. Blood samples were collected followed by PBMCs isolation, total RNA extraction, reverse transcription and finally, quantitative polymerase chain reaction (qPCR) using SYBR Green DNA binding dye. Expression levels of PD-L1 were calculated and then compared with clinicopathological parameters of the patients in addition to initial therapeutic response. Results: A significant difference was detected for PD-L1 expression levels in breast cancer patients compared to controls. A significant association with age, metastatic breast cancer, estrogen receptor (ER) negative status as well as high concentrations of cancer antigen 15-3 (CA15-3) was detected. On the other hand, no significant association was recognized with tumor size, lymph nodal status, histopathological type, grade, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER-2) status, triple negative, among de novo and recurrent metastatic patients and for the number of metastatic sites as well as the therapeutic response. Conclusions: This study paves the way of the use of PD-L1 as a noninvasive prognostic and diagnostic biomarker for poor prognosis of breast cancer.

scholarly journals Opioid Use Outcomes Among Female Breast Cancer Patients Using Adjuvant Endocrine Therapy Regimens

2017 ◽  
Vol 20 (9) ◽  
pp. A459
Author(s):  
X Tan ◽  
F Camacho ◽  
V LeBaron ◽  
L Blackhall ◽  
R Balkrishnan
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Female Breast Cancer ◽  
Adjuvant Endocrine Therapy ◽  
Breast Cancer Patients ◽  
Opioid Use ◽  
Female Breast

Perinatal factors, female breast cancer, and associated risk factors in Puerto Rico: evidence from the Atabey epidemiology of breast cancer study

2022 ◽  
Author(s):  
Lindsey J. Mattick ◽  
Cruz M. Nazario ◽  
Rosa V. Rosario-Rosado ◽  
Michelle Schelske-Santos ◽  
Imar Mansilla-Rivera ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Puerto Rico ◽  
Female Breast Cancer ◽  
Perinatal Factors ◽  
Cancer Study ◽  
Female Breast ◽  
Breast Cancer Study ◽  
Associated Risk Factors
Sign in / Sign up

Export Citation Format

Share Document